Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details Textual)

v3.20.1
Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 16, 2019
Sep. 30, 2014
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Jun. 30, 2016
Feb. 27, 2021
Jun. 30, 2019
Stockholders Equity Note [Line Items]                  
Preferred stock, par value     $ 0.001   $ 0.001       $ 0.001
Preferred stock, shares authorized     5,000,000   5,000,000       5,000,000
Preferred stock special voting shares issued     1   1       1
Common stock, shares authorized     95,000,000   95,000,000       95,000,000
Common stock, par value     $ 0.001   $ 0.001       $ 0.001
Common stock, shares issued (in shares)     11,427,132   11,427,132       3,839,358
Common stock issued under the 2017 Plan     1,250   1,250        
Warrants are exercisable, per shares     $ 0.64   $ 0.64        
Issued warrants to the underwriters     250,000   250,000        
Proceeds from warrants exercised         $ 26,550 $ 726,179      
Unvested stock options     247,605   247,605       84,990
Warrants exercise price     $ 0.64   $ 0.64        
2017 Omnibus Incentive Plan [Member]                  
Stockholders Equity Note [Line Items]                  
Common stock, shares issued (in shares)     780,000   780,000        
Common stock, shares outstanding     164,235   164,235        
Common stock issued under the 2017 Plan     614,515   614,515        
Percentage of fully diluted shares of common stock         8.00%        
2017 Omnibus Incentive Plan [Member] | Board of Directors [Member]                  
Stockholders Equity Note [Line Items]                  
Legacy plan, description         The Company's board of directors approved an increase in the number of shares of common stock available to be issued under the 2017 Plan by 1,500,000. The increase brings the total number of shares available under the 2017 Plan to 2,280,000.        
2017 Omnibus Incentive Plan [Member] | Officers and Directors [Member]                  
Stockholders Equity Note [Line Items]                  
Expiry date         Nov. 12, 2029        
Legacy plan, description         The Company’s board of directors approved an aggregate 1,041,016 stock options to officers and directors of the Company. Of the total grant, 549,199 stock options are subject to stockholder approval of the 2017 Plan share increase. The total grant date aggregate fair value of the remaining 491,817 stock options granted was $238,760. All of these stock options granted to officers and directors have an exercise price of $0.61 and expire on September 5, 2029. Of the 1,041,016 stock options approved by the board for the grant, 375,000 vest pro rata monthly over one year from the date of approval by the board of directors and 666,016 vest as to one-sixth on the six-month anniversary of the date of approval by the board of directors with the remaining five-sixths vesting pro rate monthly over 30 months commencing on the seven-month anniversary of the board of directors approval date.        
Employee Stock Option [Member]                  
Stockholders Equity Note [Line Items]                  
Stock options exercisable     531,145   531,145        
Number of stock options outstanding     778,750   778,750       288,183
Aggregate intrinsic value of stock options outstanding     $ 0 $ 0 $ 0 0      
Aggregate intrinsic value of stock options exercisable     0 $ 0 0 $ 0      
Unrecognized compensation expense     $ 96,061   $ 96,061        
Unrecognized compensation expense, term         2 years 5 months 5 days        
Employee Stock Option [Member] | CA$ $20.00 Exercise Price [Member]                  
Stockholders Equity Note [Line Items]                  
Stock options exercise price     $ 14.11   $ 14.11        
Number of stock options outstanding     2,500   2,500        
Pre Funded Warrants [Member]                  
Stockholders Equity Note [Line Items]                  
Warrants are exercisable, per shares     $ 0.01   $ 0.01        
Issued warrants to the underwriters     2,655,000   2,655,000        
Proceeds from warrants exercised         $ 26,550        
Warrants exercise price     $ 0.01   $ 0.01        
Warrant [Member]                  
Stockholders Equity Note [Line Items]                  
Warrants are exercisable, per shares               $ 59.30  
Issued warrants to the underwriters     10,209,456   10,209,456       1,543,596
Warrants, description         The Company issued 530,000 warrants for services during the nine months ended March 31, 2020. 280,000 warrants are exercisable at $0.75 per share until November 18, 2023 and they vest pro rata monthly commencing December 18, 2019. 250,000 warrants are exercisable at $0.64 per share until January 20, 2024 and they vest pro rata monthly commencing February 20, 2020. The total fair value of the warrants issued was $233,176 with $133,297 being recognized during the nine months ended March 31, 2020.        
Number of warrants               4,140  
Warrants exercise price               $ 59.30  
Stock Optionst [Member]                  
Stockholders Equity Note [Line Items]                  
Legacy plan, description         Stock Options        
2020 Investor Warrant [Member]                  
Stockholders Equity Note [Line Items]                  
Underwritten public offering, description The Company closed on the sale of (i) 4,895,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), (ii) pre-funded warrants ("PFW") to purchase an aggregate of 2,655,000 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,762,500 shares of Common Stock ("2020 Investor Warrants"), including 800,000 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,012,500 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters' option to purchase additional securities, in the Company's underwritten public offering (the "Offering"). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.                
Underwriting discounts and commissions amount $ 6,582,966                
Warrants are exercisable, per shares $ 1.00                
Expiry date Aug. 16, 2024                
Warrants exercise price $ 1.00                
2020 Investor Warrant [Member] | Underwriting Offering [Member]                  
Stockholders Equity Note [Line Items]                  
Warrants are exercisable, per shares $ 1.15                
Expiry date Aug. 14, 2022                
Underwriter warrants commencing date Feb. 10, 2020                
Issued warrants to the underwriters 377,500                
Warrants exercise price $ 1.15                
2020 Investor Warrant [Member] | Pre Funded Warrants [Member]                  
Stockholders Equity Note [Line Items]                  
Warrants are exercisable, per shares $ 0.01                
Expiry date Aug. 16, 2019                
Warrants exercise price $ 0.01                
Series B Preferred Stock [Member]                  
Stockholders Equity Note [Line Items]                  
Preferred stock, shares issued     648,613   648,613       673,613
Preferred stock, shares outstanding     648,613   648,613       673,613
Preferred stock, rate of dividend             9.00%    
Purchase price of shares             $ 80.00    
Convertible preferred stock             0.25    
Conversion price             $ 32.00    
Conversion of series B preferred stock to common stock, shares     3,700 4,735 11,100 14,430      
Issue of shares             902,238    
Bid price             $ 8.00    
Final closing date             5 years    
Direct increase in accumulated deficit     $ 1,473 $ 23,202 $ 6,071 $ 75,477      
Common stock are issuable upon conversion         162,177 210,279      
Liquidation value     $ 5,188,904   $ 5,188,904       $ 5,388,904
Series A Preferred Stock [Member]                  
Stockholders Equity Note [Line Items]                  
Preferred stock, shares issued     278,530   278,530       278,530
Preferred stock, shares outstanding     278,530   278,530       278,530
Liquidation value     $ 278,530   $ 278,530       $ 278,530
Series A Preferred Stock [Member] | Exchange Agreement [Member]                  
Stockholders Equity Note [Line Items]                  
Preferred stock, par value   $ 1              
Preferred stock, shares issued   278,530              
Preferred stock, rate of dividend   3.00%